Advanced

Medical therapy versus transurethral resection of the prostate (TURP) for the treatment of symptomatic benign prostatic enlargement (BPE) : a cost minimisation analysis

Davis, Niall F.; Jack, G. S.; Witjes, W. P.; Bjartell, A. LU ; Caris, C.; Patel, A.; de la Taille, A.; Lawrentschuk, N.; Bolton, D. M. and Tubaro, A. (2019) In World Journal of Urology 37(5). p.873-878
Abstract

Purpose: A cost minimisation analysis compares the costs of different interventions’ to ascertain the least expensive over time. We compared different prostate targeted drug treatments with TURP to identify the optimal cost saving duration of a medical therapy for symptomatic benign prostatic enlargement (BPE). Methods: The Evolution registry is a prospective, multicentre registry, conducted by the European Association of Urology Research Foundation (EAUrf) for 24 months in 5 European countries. Evolution was designed to register the management of symptomatic BPE in clinical practice settings in 5 European countries. Direct cost evaluation associated with prostate targeted medical therapies and TURP was also recorded and analysed.... (More)

Purpose: A cost minimisation analysis compares the costs of different interventions’ to ascertain the least expensive over time. We compared different prostate targeted drug treatments with TURP to identify the optimal cost saving duration of a medical therapy for symptomatic benign prostatic enlargement (BPE). Methods: The Evolution registry is a prospective, multicentre registry, conducted by the European Association of Urology Research Foundation (EAUrf) for 24 months in 5 European countries. Evolution was designed to register the management of symptomatic BPE in clinical practice settings in 5 European countries. Direct cost evaluation associated with prostate targeted medical therapies and TURP was also recorded and analysed. Results: In total, 1838 men were enrolled with 1246 evaluable at 24 months. Medical therapies were more cost saving than TURP for treatment durations ranging from 2.9 to 70.4 years. Cost saving depended on both medication class and individual country assessed. Daily tamsulosin monotherapy was more cost saving than TURP for ≤ 13.9 years in Germany compared to ≤ 32.7 years in Italy. Daily finasteride monotherapy was more cost saving for ≤ 5.9 years in France compared to ≤ 36.9 years in Spain. Combination therapy was more cost saving for ≤ 5.9 years for Italian patients versus ≤ 13.8 years in Germany. Conclusions: BPE medical management was more cost saving than TURP for different specific treatment durations. Information from this study will allow clinicians to convey medical and surgical costs over time, to both patients and payors alike, when considering BPE treatment.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Benign prostatic enlargement, Benign prostatic hyperplasia, BPE, BPH, Cost minimisation analysis
in
World Journal of Urology
volume
37
issue
5
pages
873 - 878
publisher
Springer
external identifiers
  • scopus:85052662053
ISSN
0724-4983
DOI
10.1007/s00345-018-2454-9
language
English
LU publication?
yes
id
da4d5269-af36-44b8-a1ab-ffe3ceb0e5c8
date added to LUP
2018-10-04 13:25:56
date last changed
2019-09-17 04:39:42
@article{da4d5269-af36-44b8-a1ab-ffe3ceb0e5c8,
  abstract     = {<p>Purpose: A cost minimisation analysis compares the costs of different interventions’ to ascertain the least expensive over time. We compared different prostate targeted drug treatments with TURP to identify the optimal cost saving duration of a medical therapy for symptomatic benign prostatic enlargement (BPE). Methods: The Evolution registry is a prospective, multicentre registry, conducted by the European Association of Urology Research Foundation (EAUrf) for 24 months in 5 European countries. Evolution was designed to register the management of symptomatic BPE in clinical practice settings in 5 European countries. Direct cost evaluation associated with prostate targeted medical therapies and TURP was also recorded and analysed. Results: In total, 1838 men were enrolled with 1246 evaluable at 24 months. Medical therapies were more cost saving than TURP for treatment durations ranging from 2.9 to 70.4 years. Cost saving depended on both medication class and individual country assessed. Daily tamsulosin monotherapy was more cost saving than TURP for ≤ 13.9 years in Germany compared to ≤ 32.7 years in Italy. Daily finasteride monotherapy was more cost saving for ≤ 5.9 years in France compared to ≤ 36.9 years in Spain. Combination therapy was more cost saving for ≤ 5.9 years for Italian patients versus ≤ 13.8 years in Germany. Conclusions: BPE medical management was more cost saving than TURP for different specific treatment durations. Information from this study will allow clinicians to convey medical and surgical costs over time, to both patients and payors alike, when considering BPE treatment.</p>},
  author       = {Davis, Niall F. and Jack, G. S. and Witjes, W. P. and Bjartell, A. and Caris, C. and Patel, A. and de la Taille, A. and Lawrentschuk, N. and Bolton, D. M. and Tubaro, A.},
  issn         = {0724-4983},
  keyword      = {Benign prostatic enlargement,Benign prostatic hyperplasia,BPE,BPH,Cost minimisation analysis},
  language     = {eng},
  number       = {5},
  pages        = {873--878},
  publisher    = {Springer},
  series       = {World Journal of Urology},
  title        = {Medical therapy versus transurethral resection of the prostate (TURP) for the treatment of symptomatic benign prostatic enlargement (BPE) : a cost minimisation analysis},
  url          = {http://dx.doi.org/10.1007/s00345-018-2454-9},
  volume       = {37},
  year         = {2019},
}